News Novo Nordisk's fling with Hims & Hers ends in a bust-up The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.
News Senator says ACIP next meeting should be postponed Republican Senator Bill Cassidy says tomorrow's meeting of the CDC's vaccines advisory committee should be delayed as the new members may be biased.
News ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.
News NICE backs use of MSD's KEYTRUDA for triple-negative breast ... For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy at an earlier stage of their treatment journey, as Merck & Co/MSD'
Events Partner Content IMPACCT:RWE - Real-World Evidence Conference, Boston 2018 Real-World Evidence Conference
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.